Mast cells in meningiomas and brain inflammation by unknown
REVIEW Open Access
Mast cells in meningiomas and brain
inflammation
Stavros Polyzoidis1, Triantafyllia Koletsa2, Smaro Panagiotidou3,4, Keyoumars Ashkan1
and Theoharis C. Theoharides3,4,5,6,7*
Abstract
Background: Research focus in neuro-oncology has shifted in the last decades towards the exploration of tumor
infiltration by a variety of immune cells and their products. T cells, macrophages, B cells, and mast cells (MCs) have
been identified.
Methods: A systematic review of the literature was conducted by searching PubMed, EMBASE, Google Scholar, and
Turning Research into Practice (TRIP) for the presence of MCs in meningiomas using the terms meningioma,
inflammation and mast cells.
Results: MCs have been detected in various tumors of the central nervous system (CNS), such as gliomas, including
glioblastoma multiforme, hemangioblastomas, and meningiomas as well as metastatic brain tumors. MCs were
present in as many as 90 % of all high-grade meningiomas mainly found in the perivascular areas of the tumor. A
correlation between peritumoral edema and MCs was found.
Interpretation: Accumulation of MCs in meningiomas could contribute to the aggressiveness of tumors and to
brain inflammation that may be involved in the pathogenesis of additional disorders.
Introduction
Meningiomas are primary extra-axial tumors of the central
nervous system (CNS) with an incidence of ~2 in 100,000
in adults [1]. There is an approximate 3:1 female predom-
inance of these tumors mainly attributed to the action of
oestrogens [2–4]. While meningiomas represent 15 % of
intracranial, 25 % of intraspinal, and 28 % of primary CNS
tumors, they usually are not at the center of research focus,
probably due to their predominantly benign nature, which
results in favorable outcomes. However, a minority of men-
ingiomas is found to be more aggressive, invade brain par-
enchyma, present with significant degree of peritumoral
edema, recur, and subsequently have an aggressive course
with increased morbidity and mortality [5].
Meningiomas are commonly associated with headaches,
imbalance, vision disturbance, and other neurologic prob-
lems [6] that could be quite debilitating. Based on the
2007 (current) classification and grading system of the
World Health Organization (WHO) for nervous tissue tu-
mors [7], meningiomas belong to the meningothelial-cell
tumors of the meninges and are classified in three grades
(Table 1): grade I—slow growing, noncancerous; grade
II—atypical with mixed noncancerous and cancerous fea-
tures; and grade III—cancerous and fast growing. The vast
majority of meningiomas is graded as I and is benign [5]
with treatment consisting solely of surgical resection,
which results in recurrence rates of 2–3 % following total
resection [8]. For selected small or incompletely excised
tumors, focused radiotherapy is an additional option [9].
However, treatment of meningiomas encasing crucial
neural and vascular structures, and of more aggressive
histological types, such as anaplastic (grade III), can be
more challenging. The current standard of care for the
latter comprises surgery and additional radiotherapy,
which contributes to a mean overall survival of 3.3 years
for anaplastic meningiomas based on a retrospective study
[1, 10]. Mean progression-free survival is 11.5 and 2.7 years,
respectively [11].
Mainstream theory about tumorigenesis of meningi-
omas favors origin from arachnoid cap cells, while
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intraventricular ones probably develop from meningothe-
lial inclusion bodies of the tela choroidea arachnoid [12].
Tumor formation can be triggered or affected by various
factors, such as genetic [classically the neurofibromatosis
2 (NF2) gene] [13, 14], previous radiotherapy, and possibly
head trauma [15, 16]. Meningiomas can be infiltrated by
various types of cells, mainly of the immune system, such
as macrophages, CD8 lymphocytes, and mast cells (MCs)
[17, 18]. Some meningioma variants have been associated
with systematic inflammatory syndromes as well, for ex-
ample, Castleman’s syndrome [19]. This could either rep-
resent an innate immune response to the newly forming
tumor or could be a factor contributing to tumorigenesis.
As such, it has been shown that common variations in the
genetics of the innate immune system, such as T-cell regu-
lation, chronic inflammation, IgE, and allergic reactions,
may increase the risk of meningioma [20–24]. Presently,
the exact nature of this interaction between meningiomas
and the immune system, and its potential effect on tumor
growth, remains unclear.
A retrospective immunohistochemical study investi-
gated mononuclear cell infiltration in a series of 34 men-
ingiomas [18]. Such infiltrates mainly comprised of T cells
and macrophages, with the latter being significantly asso-
ciated with high cellularity, nuclear atypia, and frequent
mitotic figures intra- and perivascularly. MCs were seen
in 9/32 (28 %) tumors, among which the most prevalent
subtype was the syncytial in agreement with previous
studies. Prognostic significance of this finding was unclear
in this study.
MCs of various phenotypes were found mainly peri-
vascularly and sporadically in lobules of connective tis-
sue in all types of meningiomas, including malignant
ones independent of growth rate, grading, and the de-
gree of calcification [25].
A rare case of a convexity meningioma with an
unusually high number of MCs, which presented as
chronic subdural hematoma, was described by Popovic
et al. [26]. It was suggested that intratumoral histamine
release, histamine-associated vasodilation, and subse-
quent tumoral hemorrhage in MC-rich meningiomas
may be an underlying mechanism in a small proportion
of meningioma-related subdural hematomas.
Incidental findings on meningiomas and MCs have also
been reported in the context of studies with other objec-
tives. During examination of the distribution of the glial fi-
brillary acidic protein (GFAP) in 131 paraffin-embedded
sections of brain neoplasms deriving from either surgical
or postmortem specimens [27], MCs were identified in
one case of meningothelial meningioma [28].
Methods
Objectives
The aim of this study was to review the literature investi-
gating the presence of MCs in meningiomas and their po-
tential interaction. More specifically, the literature was
reviewed for the role of this interface and its contribution
to tumorigenesis, biological behavior, tumor growth, and
tumor suppression.
Selection of articles
A systematic review of the literature was conducted by a
thorough online search in PubMed, EMBASE, Google
Scholar, and Turning Research into Practice (TRIP) to re-
trieve all articles evaluating the presence and role of MCs
in intracranial meningiomas. In the PubMed MeSH data-
base system, we used the terms meningioma, inflamma-
tion and mast cells [“Meningiomas” (Mesh) AND “Mast
cells” (Mesh)]. Furthermore, to eliminate the chance of
missing any other published data, references from past
relevant publications were also evaluated. Perspective and
retrospective clinical studies, including case reports, as
well as experimental studies in animals were included only
in the English language.
Results
Mast cells in brain inflammation
There is growing interest is the presence of MCs in
meningiomas, because of the conflicting reports with
regard to the association of MCs with meningioma grade
[24, 29, 30]. Furthermore, there is increasing evidence
suggesting MCs may stimulate neoplastic growth [31, 32],
while others support a potential dual role of MCs contrib-
uting both to tumorigenesis and tumor-suppression pro-
cesses in various types of cancers [33].
MCs originate from a bone marrow progenitor and sub-
sequently develop different phenotype characteristics lo-
cally in tissues. Their range of functions is wide and
includes participation in allergic reactions, innate and
adaptive immunity, inflammation, and autoimmunity [34].
In the human brain, MCs can be located in various areas,
such as the pituitary stalk, the pineal gland, the area post-
rema, the choroid plexus, thalamus, hypothalamus, and
the median eminence [35]. In the meninges, they are found
within the dural layer in association with vessels and termi-
nals of meningeal nociceptors [36]. MCs have a distinct
feature compared to other hematopoietic cells in that they
reside in the brain [37]. MCs contain numerous granules
and secrete an abundance of prestored mediators such as
corticotropin-releasing hormone (CRH), neurotensin (NT),
substance P (SP), tryptase, chymase, vasoactive intestinal
Table 1 Classification of meningiomas
1. Grade I. Meningothelial, fibrous (fibroblastic), transitional (mixed),
psammomatous, angiomatous, microcystic, secretory,
lymphoplasmacyte-rich, metaplastic
2. Grade II. Chordoid, clear cell, atypical, brain-invasive
3. Grade III. Papillary, rhabdoid, and anaplastic (malignant)
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peptide (VIP), vascular endothelial growth factor (VEGF),
TNF, prostaglandins, leukotrienes, and varieties of chemo-
kines and cytokines some of which are known to disrupt
the integrity of the blood-brain barrier (BBB) [38–40].
They key role of MCs in inflammation [34] and in the
disruption of the BBB [41–43] suggests areas of import-
ance for novel therapy research. Increasing evidence also
indicates that MCs participate in neuroinflammation dir-
ectly [44–46] and through microglia stimulation [47], con-
tributing to the pathogenesis of such conditions such as
headaches, [48] autism [49], and chronic fatigue syndrome
[50]. In fact, a recent review indicated that peripheral in-
flammatory stimuli can cause microglia activation [51],
thus possibly involving MCs outside the brain.
Mast cells in meningiomas
MCs have been found to infiltrate both primary and meta-
static tumors [52]. For instance, MCs infiltrated and pro-
liferated both in the tumor mass and in the area adjacent
to tumor-associated vessels in an experimental model of
high-grade gliomas, including glioblastoma multiforme
[53]. In addition, stem cell factor (SCF), the main growth
factor of MCs, was mainly expressed around the tumor-
associated vessels, and it was proposed that the tumor-
derived CXCL12/CXCR4 attracted MCs [53].
Polajeva et al. reported that MCs were detected in both
low- and high-grade gliomas [54], and it was concluded
that (a) MC accumulation in these tumors increased as
grade malignancy increased, (b) neutralization of the
glioma-derived macrophage migration inhibitory factor
(MIF) reduced the extent of MC migration, (c) the magni-
tude of MC recruitment correlated with the level of MIF,
and (d) MIF-induced accumulation of MCs in vivo was as-
sociated with activation of the signal transducer and acti-
vator of transcription 5 (STAT5) [54]. Additionally, MCs
have been detected in increased numbers in the infiltrat-
ing zones of medulloblastomas and gliomas [55], while
they were also found to be erythropoietin (EPO)-positive
in 50 % of a series of hemangioblastoma specimens [56].
Moreover, it has been proposed that metastatic brain
tumors can be promoted by stress (unavoidable in pa-
tients with cancer) [57] which activates brain MCs to
disrupt the BBB via the CRH pathway [58]. This in-
creases BBB permeability for primary cancer cells de-
riving from the periphery, which can subsequently
infiltrate brain parenchyma and metastasize as was
shown for rat mammary adenocarcinoma [59]. In two
case reports, breast cancer cells were reported to be as-
sociated with meningiomas [60, 61] and breast cancer
may be concurrent with meningiomas [62]. Immune re-
sponses, such as the peritumoral collection of MCs, are
increasingly considered to augment tumor growth and
metastasis [33, 57, 63].
Two retrospective studies [24, 29] evaluated MCs, by
tryptase immunostaining, in a series of meningiomas of
various grades. Specimens were divided in two groups of
low-grade meningiomas (WHO grade I) and high-grade
meningiomas (WHO grades II and III). In the first study
[24], 70 cases were analyzed. In the group of low-grade tu-
mors (n = 63), MCs were seen in 20/63 cases (31.8 %),
with strong diffused immunoreaction in 8/20 mostly next
to blood vessels disseminated intratumorally; all psammo-
matous, secretory, and meningothelial meningiomas were
negative for MCs, whereas all fibrous and transitional
meningiomas were positive. Interestingly, CT brain im-
ages of all MC-positive low-grade meningiomas showed
marked peritumoral edema [24].
In the second group (n = 7), 6/7 (86 %) tumors were
positive for MCs and all presented with peritumoral edema
on CT. One anaplastic meningioma was strongly immuno-
positive, while the rest of the high-grade meningiomas
showed focal, but disseminated, positive immunoreaction
for tryptase [24]. The second study [29], was conducted on
154 cases, and apart from MCs, it also evaluated the ex-
pression of hypoxia-inducible factor-1 (HIF-1), which is a
marker of hypoxia found to be correlated with grade and
progression of many cancers including glioblastoma [64].
In the group of low-grade meningiomas (n = 104), MCs
were seen in 42 cases (40.4 %), with strong diffused immu-
noreaction in 17/42. In the group of high-grade meningi-
omas (n = 50), 45 (90 %) of tumors were positive for MCs,
with strong immunoreaction in 6/45 cases. MCs were ob-
served not only next to blood vessels but also within the
tumor [29].
Based on the Steinhoff classification of peritumoral
edema [65], this study showed a statistically significant as-
sociation between HIF-1 expression, tryptase expression,
and the presence of peritumoral brain edema, as well as
between MC accumulation and HIF-1 expression based
on meningioma grading [29]. MC mediators such as hista-
mine, serotonin, or VEGF might significantly contribute
to the formation of peritumoral edema.
Tirakotai et al. studied secretory meningiomas (grade I),
which were found to be infiltrated by a higher number of
MCs compared to other types (nonsecretory meningi-
omas). Higher number of MCs was found mainly in and
around the pseudopsammoma bodies of secretory men-
ingiomas [66] Eparil et al. and Tina-Suck et al. investigated
12 and 10 cases, respectively, of chordoid meningiomas
(grade II) [67, 68]. Both reported a significant number of
MCs in this meningioma variant. The first observed MCs
both within the myxoid stroma and the epithelial cell
islands, by using toluidine blue and Giemsa stains, in
100 % of cases. MCs were sparsely populated, granulated,
single in arrangement, and more frequently seen at the
interface regions [67]. The second observed MCs present
both in the connective tissue stroma and the epithelial cell
Polyzoidis et al. Journal of Neuroinflammation  (2015) 12:170 Page 3 of 8
islands in all specimens, using positive Periodic Acid
Schiff (PAS) and mucicarmine stains [68]. In contrast, an-
other study [30] reported that MCs had poor associations
with meningioma tumor grading.
Mast cells in cystic meningiomas
An interesting role of MCs in meningiomas was revealed
in a retrospective study investigating microcystic and cys-
tic changes in 397 meningiomas [69]. Such changes were
present in about 10 % of these tumors, mainly of the
meningothelial type (grade I), and were associated with
permeability disturbances and increased number of MCs.
Here we show the presence of MCs in dura and bone infil-
trated by meningioma of the meningothelial type grade 1
stained for tryptase (Fig. 1) and CD117 (c-kit, the tyrosine
kinase surface receptor for stem cell factor) (Fig. 2). It
should be noted that these MCs do not appear degranu-
lated. We recently reported that MCs infiltrating pancre-
atic adenocarcinoma were also increased, but not
degranulated in contrast to MCs in acute pancreatitis that
were increased in number, but degranulated [70].
Meningiomas and perivascular edema
Cerebral edema is quite common in intracranial meningi-
omas. In one study of 68 meningiomas evaluated by com-
puted tomography, 40 % had significant edema [71].
Another review concluded that intracranial meningiomas
were associated with brain edema in 50–66 % of cases [72].
In fact, edema has been considered a prognostic factor for
meningiomas and metastases, but not gliomas [73]. More-
over, there was a strong correlation between brain edema
and shape of tumor margins and signal intensity on
magnetic resonance imaging of 51 meningiomas studied
[74]. Peritumoral edema may be due to increased expres-
sion of vascular endothelial growth factor (VEGF) [75, 76].
In fact, meningiomas can secrete VEGF-A themselves [77].
It is of interest that MCs can secrete large quantities of
VEGF especially in response to CRH [78], which can be
secreted by MCs [79] and by metastatic cancer cells [80].
Meningiomas are well known to present with severe
headaches, even when tumors are small with little edema,
and mass effect alone is insufficient to account for this
symptom [81, 82]. It is therefore of interest that MCs have
been implicated in the pathogenesis of migraines [38] and
meningeal MC-neuron interactions are increasingly in-
voked in the pathophysiology of headaches [83, 84]. Men-
ingeal inflammation was also regarded critical in seizures
[85], and there have been a number of cases of patients
with seizures due to underlying mastocytosis [46, 86].
The association of MCs with perivascular edema is
also important because it may indicate disruption of the
BBB, which worsens by stress and contributes to brain
metastases [57], multiple sclerosis [87], autism [35, 88],
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Fig. 1 Photomicrographs of tissue samples of dura and bone infiltrated by meningioma of the meningothelial type grade I obtained from a
brain lesion following a left-left frontotemporal craniectomy. Mast cells were stained immunohistochemically for the presence of tryptase
(brown color). a Dura showing the upper unaffected part and the lower part infiltrated meningioma cells (blue) and accumulated mast cells
(brown); magnification = ×40. b Unaffected dura; magnification = ×100. c Bone infiltrated by meningioma cells showing a cluster of mast cells;
magnification = ×100. d Mast cells surrounding clusters of meningioma cells infiltrating the dura; magnification = ×400. e One mast cell
surrounded by meningioma cells; this mast cell does not appear to be degranulated. Bar = 15 μm
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investigate the presence of occult meningiomas in such
disorders.
Treatment options
Brain edema may be reduced with the use of glucocorti-
coids or anti-angiogenic therapy [77].
Cyclooxygenase (COX) inhibitors have also been con-
sidered for the treatment of brain edema [73, 90] espe-
cially because COX-2 expression has been reported in
astrocyte and microglia in humans [91]. It is of interest
that certain natural flavonoids, such as quercetin (3, 5, 7-3΄
4΄-pentahydroxyflavone), inhibit COX-2 and angiogenesis
[92, 93], and its structural analog luteolin (5,7-3′4′-tetrahy-
droxyflavone) inhibits COX-2 in glioblastoma cells [94].
Quercetin also has antiproliferative activity against human
meningiomas [95] and gliomas [96, 97]. Luteolin has syner-
gistic action with COX-2 inhibitors on inducing apoptosis
of breast cancer cells [98].
Both quercetin [99] and luteolin inhibit MCs [99–101],
especially MC-derived VEGF release. Luteolin also inhibits
activation of auto-immune T cells [102, 103].
A methylated luteolin analog (6-methoxyluteolin) was
shown to inhibit IgE-stimulated histamine release from
human basophilic KU812F [104]. Moreover, we recently
showed that tetramethoxyluteolin is a more potent in-
hibitor of human cultured MCs than luteolin [105].
Luteolin also inhibits activation and proliferation of
microglia [106–109], which have been implicated in aut-
ism [110]. A luteolin/quercetin-containing formulation
in olive fruit oil significantly improved attention and be-
havior in children with autism [111, 112]. It is interest-
ing that oleocanthal present in olive oil was shown to
have COX inhibitory activity [113].
Flavonoids are naturally occurring compounds found
mostly in green plants, herbs, and seeds with potent
antioxidant, anti-inflammatory, and anticancer properties
[114]. Recent reviews have discussed the use of flavonoids
in neuropsychiatric [115, 116] and neurodegenerative
[117, 118] diseases, especially luteolin in the prevention
and/or treatment of brain fog [119].
Conclusion
There is growing evidence that the accumulation of
MCs in meningiomas, mainly in perivascular areas, is as-
sociated with the presence of peritumoral edema, espe-
cially in high-grade tumors. Furthermore, meningeal
MCs may contribute to edema and inflammation in-
volved in headaches and possibly seizures. Finally, men-
ingeal MCs may regulate permeability of the BBB and
contribute to the pathogenesis of brain metastases, mul-
tiple sclerosis, and autism.
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a Unaffected dura showing two mast cells. b Dura infiltrated by meningioma cells showing a number of mast cells (brown color). Magnification = ×200
Polyzoidis et al. Journal of Neuroinflammation  (2015) 12:170 Page 5 of 8
Received: 7 August 2015 Accepted: 1 September 2015
References
1. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al.
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A
RANO review. J Neurosurg. 2015;122:4–23.
2. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and
beta in human meningiomas. J Neurooncol. 1999;42:109–16.
3. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Expression of
androgen and progesterone receptors in primary human meningiomas.
J Neurosurg. 1993;78:456–62.
4. Probst-Cousin S, Villagran-Lillo R, Lahl R, Bergmann M, Schmid KW, Gullotta
F. Secretory meningioma: clinical, histologic, and immunohistochemical
findings in 31 cases. Cancer. 1997;79:2003–15.
5. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al.
CBTRUS statistical report: primary brain and central nervous system tumors
diagnosed in the United States in 2006–2010. Neuro Oncol.
2013;15 Suppl 2:ii1–56.
6. Madhusoodanan S, Patel S, Reinharth J, Hines A, Serper M. Meningioma and
psychiatric symptoms: a case report and brief review. Ann Clin Psychiatry.
2015;27:126–33.
7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007;114:97–109.
8. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL.
Meningioma: analysis of recurrence and progression following neurosurgical
resection. J Neurosurg. 1985;62:18–24.
9. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM.
Radiation therapy in the treatment of partially resected meningiomas.
Neurosurgery. 1987;20:525–8.
10. Smith SJ, Boddu S, Macarthur DC. Atypical meningiomas: WHO moved the
goalposts? Br J Neurosurg. 2007;21:588–92.
11. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and
anaplastic meningiomas: prognostic implications of clinicopathological
features. J Neurol Neurosurg Psychiatry. 2008;79:574–80.
12. Bret P, Gharbi S, Cohadon F, Remond J. Meningioma of the lateral ventricle.
3 recent cases. Neurochirurgie. 1989;35:5–12.
13. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al.
Evidence for the complete inactivation of the NF2 gene in the majority of
sporadic meningiomas. Nat Genet. 1994;6:180–4.
14. Mawrin C, Perry A. Pathological classification and molecular genetics of
meningiomas. J Neurooncol. 2010;99:379–91.
15. Phillips LE, Koepsell TD, van BG, Kukull WA, Gehrels JA, Longstreth Jr WT.
History of head trauma and risk of intracranial meningioma: population-
based case–control study. Neurology. 2002;58:1849–52.
16. Preston-Martin S, Pogoda JM, Schlehofer B, Blettner M, Howe GR, Ryan P,
et al. An international case–control study of adult glioma and meningioma:
the role of head trauma. Int J Epidemiol.
1998;27:579–86.
17. Rossi ML, Cruz SF, Hughes JT, Esiri MM, Coakham HB. Immunocytochemical
study of the cellular immune response in meningiomas. J Clin Pathol.
1988;41:314–9.
18. Bo L, Mork SJ, Nyland H. An immunohistochemical study of mononuclear
cells in meningiomas. Neuropathol Appl Neurobiol. 1992;18:548–58.
19. Kepes JJ, Chen WY, Connors MH, Vogel FS. “Chordoid” meningeal tumors in
young individuals with peritumoral lymphoplasmacellular infiltrates causing
systemic manifestations of the Castleman syndrome. A report of seven
cases. Cancer. 1988;62:391–406.
20. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, et al. Risk of
meningioma and common variation in genes related to innate immunity.
Cancer Epidemiol Biomarkers Prev. 2010;19:1356–61.
21. Barnett GH, Chou SM, Bay JW. Posttraumatic intracranial meningioma: a
case report and review of the literature. Neurosurgery. 1986;18:75–8.
22. Kunz T, Marklund N, Hillered L, Oliw EH. Cyclooxygenase-2, prostaglandin
synthases, and prostaglandin H2 metabolism in traumatic brain injury in the
rat. J Neurotrauma. 2002;19:1051–64.
23. Ragel BT, Jensen RL, Couldwell WT. Inflammatory response and
meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors.
Neurosurg Focus. 2007;23:E7.
24. Reszec J, Hermanowicz A, Kochanowicz J, Turek G, Mariak Z, Chyczewski
L. Mast cells evaluation in meningioma of various grades. Folia Histochem
Cytobiol. 2012;50:542–6.
25. Lolova I, Ivanova A. A histochemical study of meningiomas. Acta
Neuropathol. 1972;20:110–21.
26. Popovic EA, Lyons MK, Scheithauer BW, Marsh WR. Mast cell-rich convexity
meningioma presenting as chronic subdural hematoma: case report and
review of the literature. Surg Neurol. 1994;42:8–13.
27. Tascos NA, Parr J, Gonatas NK. Immunocytochemical study of the glial
fibrillary acidic protein in human neoplasms of the central nervous system.
Hum Pathol. 1982;13:454–8.
28. Christie KN, Stoward PJ. Endogenous peroxidase in mast cells localized with
a semipermeable membrane technique. Histochem J. 1978;10:425–33.
29. Reszec J, Hermanowicz A, Rutkowski R, Bernaczyk P, Mariak Z, Chyczewski
L. Evaluation of mast cells and hypoxia inducible factor-1 expression in
meningiomas of various grades in correlation with peritumoral brain
edema. J Neurooncol. 2013;115:119–25.
30. Jabini R, Moradi A, Afsharnezhad S, Ayatollahi H, Behravan J, Raziee HR, et al.
Pathodiagnostic parameters and evaluation of O(6)- methyl guanine methyl
transferase gene promoter methylation in meningiomas. Gene.
2014;538:348–53.
31. Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: introduction and
overview. Adv Exp Med Biol. 2011;716:2–12.
32. Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim
Biophys Acta. 1822;2012:2–8.
33. Theoharides TC, Conti P. Mast cells: the JEKYLL and HYDE of tumor growth.
Trends Immunol. 2004;25:235–41.
34. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis and related
diseases. New Engl J Med. 2015. in press
35. Theoharides TC, Stewart JM, Panagiotidou S. Mast Cells, Brain Inflammation
and Autism. Eur J Pharmacol. 2015. in press
36. Dimitriadou V, Rouleau A, Trung Tuong MD, Newlands GJF, Miller HRP,
Luffau G, et al. Functional relationships between sensory nerve fibers and
mast cells of dura mater in normal and inflammatory conditions.
Neuroscience. 1997;77:829–39.
37. Silver R, Curley JP. Mast cells on the mind: new insights and opportunities.
Trends Neurosci. 2013.
38. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis
K, et al. Mast cell activation and autism. Biochim Biophys Acta.
1822;2012:34–41.
39. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci.
1990;46:607–17.
40. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the
blood-brain-barrier. Front Biosci. 2007;12:1615–28.
41. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly
R, et al. Corticotropin-releasing hormone (CRH) and brain mast cells
regulate blood-brain-barrier permeability induced by acute stress.
J Pharmacol Exp Ther. 2002;303:1061–6.
42. Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy
and inflammation. Ann NY Acad Sci. 2006;1088:78–99.
43. Ribatti D. The crucial role of mast cells in blood-brain barrier alterations. Exp
Cell Res. 2015.
44. Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J, et al. The
role of mast cells in neuroinflammation. Acta Neuropathol. 2013;125:637–50.
45. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners
in crime? Immunology. 2014;141:314–27.
46. Theoharides TC, Zhang B. Neuro-Inflammation, blood-brain barrier, seizures
and autism. J Neuroinflammation. 2011;8:168.
47. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners
in crime? Immunology. 2014;141:314–27.
48. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A.
The role of mast cells in migraine pathophysiology. Brain Res Rev.
2005;49:65–76.
49. Theoharides TC, Asadi S, Patel A. Focal brain inflammation and autism.
J Neuroinflammation. 2013;10:46.
50. Vasiadi M, Newman J, Theoharides TC. Isoflavones inhibit poly(I:C)-induced
serum, brain, and skin inflammatory mediators - relevance to chronic
fatigue syndrome. J Neuroinflammation. 2014;11:168.
51. Hoogland IC, Houbolt C, van Westerloo DJ, van Gool WA, van de BD.
Systemic inflammation and microglial activation: systematic review of
animal experiments. J Neuroinflammation. 2015;12:114.
Polyzoidis et al. Journal of Neuroinflammation  (2015) 12:170 Page 6 of 8
52. Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol. 2015
53. Polajeva J, Sjosten AM, Lager N, Kastemar M, Waern I, Alafuzoff I, et al. Mast
cell accumulation in glioblastoma with a potential role for stem cell factor
and chemokine CXCL12. PLoS ONE. 2011;6:e25222.
54. Polajeva J, Bergstrom T, Edqvist PH, Lundequist A, Sjosten A, Nilsson G,
et al. Glioma-derived macrophage migration inhibitory factor (MIF)
promotes mast cell recruitment in a STAT5-dependent manner. Mol
Oncol. 2014;8:50–8.
55. Kumar P, Kumar S, Marsden HB, Lynch PG, Earnshaw E. Weibel-Palade
bodies in endothelial cells as a marker for angiogenesis in brain tumors.
Cancer Res. 1980;40:2010–9.
56. Tachibana O, Yamashima T, Yamashita J. Immunohistochemical study of
erythropoietin in cerebellar hemangioblastomas associated with secondary
polycythemia. Neurosurgery. 1991;28:24–6.
57. Theoharides TC, Rozniecki JJ, Sahagian G, Kempuraj D, Kalogeromitros D,
Conti P. Impact of stress and mast cells on brain metastases.
J Neuroimmunol. 2008;205:1–7.
58. Esposito P, Jacobson S, Connolly R, Gheorghe D, Theoharides TC.
Non-invasive assessment of blood-brain barrier (BBB) permeability using a
gamma camera to detect 99Technetium-gluceptate extravasation in rat
brain. Brain Res Protocols. 2001;8:143–9.
59. Rozniecki JJ, Sahagian GG, Kempuraj D, Tao K, Jocobson S, Zhang B, et al.
Brain metastases of mouse mammary adenocarcinoma is increased by
acute stress. Brain Res. 2010;1366:204–10.
60. Sayegh ET, Henderson GA, Burch EA, Reis GF, Cha S, Oh T, et al.
Intrameningioma metastasis of breast carcinoma. Rare Tumors. 2014;6:5313.
61. Okada E, Nakamura M, Koshida Y, Mukai K, Toyama Y, Matsumoto M.
Breast carcinoma metastasis to meningioma in the thoracic spine: a
case report and review of the literature. J Spinal Cord Med.
2015;38:231–5.
62. Milano MT, Grossman CE. Meningioma in breast cancer patients:
population-based analysis of clinicopathologic characteristics. Am J Clin
Oncol. 2014
63. Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med.
2008;358:1860–1.
64. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging,
pseudoprogression, and as a therapeutic target. J Neurooncol.
2009;92:317–35.
65. Kazner E, Lanksch W, Steinhoff H, Wilske J. Computerized axial tomography
of the skull - diagnostic possibilities and clinical results (author’s transl).
Fortschr Neurol Psychiatr Grenzgeb. 1975;43:487–574.
66. Tirakotai W, Mennel HD, Celik I, Hellwig D, Bertalanffy H, Riegel T. Secretory
meningioma: immunohistochemical findings and evaluation of mast cell
infiltration. Neurosurg Rev. 2006;29:41–8.
67. Epari S, Sharma MC, Sarkar C, Garg A, Gupta A, Mehta VS. Chordoid
meningioma, an uncommon variant of meningioma: a clinicopathologic
study of 12 cases. J Neurooncol. 2006;78:263–9.
68. Tena-Suck ML, Collado-Ortiz MA, Salinas-Lara C, Garcia-Lopez R, Gelista N,
Rembao-Bojorquez D. Chordoid meningioma: a report of ten cases.
J Neurooncol. 2010;99:41–8.
69. Schober R, Himuro H, Wechsler W. Cystic changes and vascular permeability
in meningiomas. Clin Neuropathol. 1988;7:16–21.
70. Karamitopoulou E, Shoni M, Theoharides TC. Increased number of
non-degranulated mast cells in pancreatic ductal adenocarcinoma but not
in acute pancreatitis. Int J Immunopathol Pharmacol. 2014;27:213–20.
71. Abe T, Black PM, Ojemann RG, Hedley-White ET. Cerebral edema in
intracranial meningiomas: evidence for local and diffuse patterns and
factors associated with its occurrence. Surg Neurol. 1994;42:471–5.
72. Buhl R, Hugo HH, Mehdorn HM. Brain oedema in secretory meningiomas.
J Clin Neurosci. 2001;8 Suppl 1:19–21.
73. Wick W, Kuker W. Brain edema in neurooncology: radiological assessment
and management. Onkologie. 2004;27:261–6.
74. Nakano T, Asano K, Miura H, Itoh S, Suzuki S. Meningiomas with brain
edema: radiological characteristics on MRI and review of the literature. Clin
Imaging. 2002;26:243–9.
75. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000;50:109–20.
76. Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral
brain oedema. Dan Med J. 2013;60:B4626.
77. Hou J, Kshettry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in
intracranial meningiomas: the emergence of vascular endothelial growth
factor-directed therapy. Neurosurg Focus. 2013;35:E2.
78. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL,
et al. Human mast cells express corticotropin-releasing hormone (CRH)
receptors and CRH leads to selective secretion of vascular endothelial
growth factor. J Immunol. 2005;174:7665–75.
79. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska
K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally
related urocortin are synthesized and secreted by human mast cells.
Endocrinology. 2004;145:43–8.
80. Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL. Ectopic
corticotropin-releasing hormone (CRH) syndrome from metastatic small
cell carcinoma: a case report and review of the literature. Diagn Pathol.
2010;5:56.
81. Feoktistov A, Diamond M. Diagnosing and understanding adult headache.
Otolaryngol Clin North Am. 2014;47:175–85.
82. Smith RM, Robertson CE, Garza I. Orthostatic headache from supratentorial
meningioma. Cephalalgia. 2015
83. Heron A, Dubayle D. A focus on mast cells and pain. J Neuroimmunol.
2013;264:1–7.
84. Hancock BW, Dandona P, Cumberland DC, Jarratt JA. Systemic
mastocytosis–central nervous system features and lymphographic
demonstration of lymph node involvement. Postgrad Med J.
1976;52:659–62.
85. Ransohoff RM. Immunology: barrier to electrical storms. Nature.
2009;457:155–6.
86. Pehlivanidis C, Fotoulaki M, Boucher W, Kempuraj D, Pang X, Konstantinidou
A, et al. Acute stress-induced seizures and loss of consciousness in a
ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol.
2002;22:221–4.
87. Karagkouni A, Alevizos M, Theoharides TC. Effect of stress on brain
inflammation and multiple sclerosis. Autoimmun Rev. 2013;12:947–53.
88. Bradstreet JJ, Pacini S, Ruggiero M. A new methodology of viewing
extra-axial fluid and cortical abnormalities in children with autism via
transcranial ultrasonography. Front Hum Neurosci. 2014;7:934.
89. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain “fog,”
inflammation and obesity: key aspects of 2 neuropsychiatric disorders
improved by luteolin. Front. Neurosci. 2015. in press
90. Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain
cancer patients: pathogenesis and management. Expert Rev Anticancer
Ther. 2013;13:1319–25.
91. Temel SG, Kahveci Z. Cyclooxygenase-2 expression in astrocytes and
microglia in human oligodendroglioma and astrocytoma. J Mol Histol.
2009;40:369–77.
92. Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, et al. Quercetin suppresses
cyclooxygenase-2 expression and angiogenesis through inactivation of P300
signaling. PLoS ONE. 2011;6:e22934.
93. de Pascual-Teresa S, Johnston KL, DuPont MS, O’Leary KA, Needs PW,
Morgan LM, et al. Quercetin metabolites downregulate cyclooxygenase-2
transcription in human lymphocytes ex vivo but not in vivo. J Nutr.
2004;134:552–7.
94. Lamy S, Moldovan PL, Ben SA, Annabi B. Biphasic effects of luteolin on
interleukin-1beta-induced cyclooxygenase-2 expression in glioblastoma
cells. Biochim Biophys Acta. 1853;2015:126–35.
95. Piantelli M, Rinelli A, Macri E, Maggiano N, Larocca LM, Scerrati M, et al.
Type II estrogen binding sites and antiproliferative activity of quercetin in
human meningiomas. Cancer. 1993;71:193–8.
96. Park MH, Min dS. Quercetin-induced downregulation of phospholipase D1
inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res
Commun. 2011;412:710–5.
97. Braganhol E, Zamin LL, Canedo AD, Horn F, Tamajusuku AS, Wink MR, et al.
Antiproliferative effect of quercetin in the human U138MG glioma cell line.
Anticancer Drugs. 2006;17:663–71.
98. Jeon YW, Suh YJ. Synergistic apoptotic effect of celecoxib and luteolin on
breast cancer cells. Oncol Rep. 2013;29:819–25.
99. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J,
Papadopoulou N, et al. Flavonols inhibit proinflammatory mediator release,
intracellular calcium ion levels and protein kinase C theta phosphorylation
in human mast cells. Br J Pharmacol. 2005;145:934–44.
100. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of
luteolin, quercetin and baicalein on immunoglobulin E-mediated
mediator release from human cultured mast cells. Clin Exp Allergy.
2000;30:501–8.
Polyzoidis et al. Journal of Neuroinflammation  (2015) 12:170 Page 7 of 8
101. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD, et al.
Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF
release from human mast cells. Int J Immunopathol Pharmacol.
2010;23:1015–20.
102. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W,
et al. Luteolin inhibits myelin basic protein-induced human mast cell
activation and mast cell dependent stimulation of Jurkat T cells. Br
J Pharmacol. 2008;155:1076–84.
103. Verbeek R, Plomp AC, van Tol EA, van Noort JM. The flavones luteolin and
apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma
production by murine and human autoimmune T cells. Biochem Pharmacol.
2004;68:621–9.
104. Shim SY, Park JR, Byun DS. 6-Methoxyluteolin from Chrysanthemum
zawadskii var. latilobum suppresses histamine release and calcium influx via
down-regulation of FcepsilonRI alpha chain expression. J Microbiol
Biotechnol. 2012;22:622–7.
105. Weng Z, Patel A, Panagiotidou S, Theoharidess TC. The novel flavone
tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin
Immunol. 2014;14:1044–52.
106. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in
microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc
Natl Acad Sci U S A. 2008;105:7534–9.
107. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y, et al.
Luteolin triggers global changes in the microglial transcriptome leading to
a unique anti-inflammatory and neuroprotective phenotype.
J Neuroinflammation. 2010;7:3.
108. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. Luteolin protects
dopaminergic neurons from inflammation-induced injury through inhibition
of microglial activation. Neurosci Lett. 2008;448:175–9.
109. Kao TK, Ou YC, Lin SY, Pan HC, Song PJ, Raung SL, et al. Luteolin inhibits
cytokine expression in endotoxin/cytokine-stimulated microglia. J Nutr
Biochem. 2011;22:612–24.
110. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, et al. Transcriptome
analysis reveals dysregulation of innate immune response genes and
neuronal activity-dependent genes in autism. Nat Commun. 2014;5:5748.
111. Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin
formulation (NeuroProtek(R)) in children with autism spectrum disorders.
Int J Immunopathol Pharmacol. 2012;25:317–23.
112. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a
formulation containing the anti-inflammatory flavonoid luteolin and its
effects on behavior in children with autism spectrum disorders. Clin Ther.
2013;35:592–602.
113. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry:
ibuprofen-like activity in extra-virgin olive oil. Nature. 2005;437:45–6.
114. Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant
flavonoids on mammalian cells: implications for inflammation, heart disease
and cancer. Pharmacol Rev. 2000;52:673–751.
115. Jager AK, Saaby L. Flavonoids and the CNS. Molecules. 2011;16:1471–85.
116. Grosso C, Valentao P, Ferreres F, Andrade PB. The use of flavonoids in
central nervous system disorders. Curr Med Chem. 2013;20:4697–719.
117. Solanki I, Parihar P, Mansuri ML, Parihar MS. Flavonoid-based therapies in the
early management of neurodegenerative diseases. Adv Nutr. 2015;6:64–72.
118. Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection
of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci.
2012;33:602–10.
119. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain “fog”,
inflammation and obesity: key aspects of neuropsychiatric disorders
improved by luteolin. Front Neurosci. 2015;9:225.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Polyzoidis et al. Journal of Neuroinflammation  (2015) 12:170 Page 8 of 8
